Education
About Us
Working with TipRanks
Follow Us
Miricor Enterprises Holdings Ltd (HK:1827)
:1827
1827 Stock Chart & Stats
HK$0.95
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.95
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1.30
Previous CloseN/A
Volume40.00K
Average Volume (3M)4.67K
Market Cap
HK$284.00M
Enterprise ValueHK$190.44M
Total Cash (Recent Filing)HK$192.17M
Total Debt (Recent Filing)HK$88.76M
Price to Earnings (P/E)26.1
Beta-0.20
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding400,000,000
10 Day Avg. Volume6,000
30 Day Avg. Volume4,666
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)3.17
Price to Sales (P/S)1.16
P/FCF Ratio4.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained free cash flow growth and very high cash conversion provide durable internal funding for R&D, working capital and debt reduction. This lowers reliance on external capital, improves financial flexibility, and supports long-term investment in product development and commercialization.
Improving Profitability MarginsMaterial margin improvement indicates better cost control and operational efficiency in core biotech operations. Higher gross and operating margins increase resilience to revenue volatility and create room to reinvest in clinical development and commercialization over multiple quarters.
Lower Leverage And Stronger Balance SheetReduced leverage and a moderate equity cushion enhance solvency and reduce interest burden, allowing management to fund strategic initiatives or withstand sector cyclicality. Improved ROE shows more effective use of shareholder capital, supporting sustainable growth execution.
Bears Say
Declining Revenue TrendA persistent top-line contraction undermines scale economics and constrains the firm's ability to fund R&D, commercialization and fixed costs internally. Continued revenue decline over multiple quarters would limit margin durability and impair long-term growth prospects in biotech markets.
Thin Net ProfitabilityWhile profitability has returned, the very low net margin leaves earnings highly sensitive to cost pressure, pricing changes, or one-time expenses. Thin margins reduce the buffer for financing innovation and make sustaining R&D spend and commercialization investments more challenging.
Limited Forward Guidance / Analyst VisibilityAbsence of guidance and limited reported call highlights reduces visibility into management's operational outlook and strategy execution. That opacity can hinder planning by partners and investors, making it harder to assess execution risk and to secure long-term commercial or financing commitments.
Miricor Enterprises Holdings Ltd News
1827 FAQ
What was Miricor Enterprises Holdings Ltd’s price range in the past 12 months?
Miricor Enterprises Holdings Ltd lowest stock price was HK$0.19 and its highest was HK$1.30 in the past 12 months.
What is Miricor Enterprises Holdings Ltd’s market cap?
Miricor Enterprises Holdings Ltd’s market cap is HK$284.00M.
When is Miricor Enterprises Holdings Ltd’s upcoming earnings report date?
Miricor Enterprises Holdings Ltd’s upcoming earnings report date is Jun 30, 2026 which is in 126 days.
How were Miricor Enterprises Holdings Ltd’s earnings last quarter?
Miricor Enterprises Holdings Ltd released its earnings results on Nov 25, 2025. The company reported -HK$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.001.
Is Miricor Enterprises Holdings Ltd overvalued?
According to Wall Street analysts Miricor Enterprises Holdings Ltd’s price is currently Overvalued.
Does Miricor Enterprises Holdings Ltd pay dividends?
Miricor Enterprises Holdings Ltd does not currently pay dividends.
What is Miricor Enterprises Holdings Ltd’s EPS estimate?
Miricor Enterprises Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Miricor Enterprises Holdings Ltd have?
Miricor Enterprises Holdings Ltd has 400,000,000 shares outstanding.
What happened to Miricor Enterprises Holdings Ltd’s price movement after its last earnings report?
Miricor Enterprises Holdings Ltd reported an EPS of -HK$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Miricor Enterprises Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1827
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Miricor Enterprises Holdings Ltd
Miricor Enterprises Holdings Limited, an investment holding company, provides medical aesthetic services in Hong Kong. It also offers a range of non-surgical medical aesthetic services, including energy-based and injection procedures. The company operates three medical aesthetic centers under the CosMax+ name. It also sells skin care products, such as cleansers, toners, serums, moisturizers, eye care products, ultraviolet protection products, and masks. Miricor Enterprises Holdings Limited was founded in 2009 and is headquartered in Causeway Bay, Hong Kong.
Technical Analysis
Water Oasis Group
―
Modern Healthcare Technology Holdings Limited
―
Perfect Medical Health Management Limited
―
Fameglow Holdings Limited
―